• Recruiting

NCT05346809: Phase 2: Isatuximab During Stem Cell Collection and Transplant in Myeloma & Lymphoma


NCT05346809: Phase 2: Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

NDMM

RRMM

isatuximab in transplant

The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.


Sponsor

Divaya Bhutani


Collaborator

Genzyme, a Sanofi Company

 

ClinicalTrials.gov Identifier: NCT05346809

Official Title: Randomized Phase 2 Trial of Isatuximab During Autologous Stem Cell Collection and Transplantation Period in Patients With Multiple Myeloma, Relapsed Hodgkin's and Non-Hodgkin's Lymphoma

First Posted : April 26, 2022


Click here to see details on ClinicalTrials.gov

 

Isatuximab : National Cancer Institute

 

Drug: Isatuximab

Other: Standard Procedures

 

Location

United States, New York

Columbia University

New York, New York, United States


Posts Archive